more efficacious and better tolerated by comparison to cisplatin in an orthotopic human breast cancer xenograft model in vivo.
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RGD peptide; integrin targeting; Pt(IV) complex; polymeric nanoparticle; breast cancer xenograft Cisplatin is one of the most widely used anticancer drugs most notably for the treatment of ovarian and testicular cancer. Current research focuses on minimizing side effects like liver and kidney toxicity and to overcoming resistance of the drug while maintaining its potency against cancer cells, thereby extending successful treatment to a wider range of human cancers. 1 For example, as a single agent, cisplatin can only achieve up to 10% response rates in pretreated breast cancer patients.
2
Only 5-10% of the Pt(II) compound cisplatin that enters cells binds to nuclear DNA, the target responsible for its anticancer activity; the remainder is associated with proteins and low molecular weight biomolecules. 3 It is therefore important to deliver as much of the injected platinum as possible to the cancer cell. A promising strategy for achieving this goal is to employ Pt(IV) complexes as prodrugs that can be intracellularly activated by reduction to generate Pt(II). 4 The greater kinetic inertness of Pt(IV) compared to more labile Pt(II) complexes has the potential to enable a larger amount of drug to arrive at the tumor site intact by avoiding side-reactions with proteins and other biomolecules in the process. Thus Pt(IV) compounds in general are expected to be less toxic and produce fewer side-effects in vivo. Pt(IV) complexes accumulated in the hypoxic tumor environment become reduced to more reactive Pt(II) analogs. 5 For increasing drug efficacy, targeted delivery to cancer cells is desirable. 6 This selectivity can be achieved by exploiting the presence of proteins upregulated in cancer cells. Among these are integrins, heterodimeric cell adhesion proteins that have been linked to both tumor angiogenesis and metastasis. 7, 8 The integrin receptor is highly upregulated in tumor-associated endothelial cells during angiogenesis in a wide range of fast growing tumors in contrast to its minimal expression in quiescent endothelial cells in most normal tissues. 9 Targeting the tumor vasculature is a powerful approach for cancer treatment because angiogenesis is essential for tumor growth and the vasculature is in direct contact with the bloodstream. 10 A prominent example of a tumor vasculature-homing peptide is the three amino acid sequence RGD motif (arginine-glycine-aspartic acid). 11 RGD motifs are present in many extracellular matrix components such as fibronectin and vitronectin and bind to integrins on the cell surface. RGD analogs are used for tumor imaging and targeting with chemotherapeutic drugs or radionuclides. For example, a conjugate of the anticancer drug doxorubicin with RGD showed improved inhibition of breast tumor growth and metastatic dissemination in mice. 10 Radiolabeled RGD peptides were targeted to xenograft tumors expressing α v β 3 integrins. [12] [13] [14] With [ 18 F]-galacto-RGD, the first RGD-based imaging agent was recently tested in humans, where it displayed highly desirable pharmacokinetics and good imaging of α v β 3 expression by PET. 15 Previously, our group described the synthesis and biological evaluation of mono-and bifunctional Pt(IV)-peptide complexes containing RGD sequences as tumor-homing devices. Owing to selective binding to tumor cells they were expected to be more effective than cisplatin, but none was able to exceed the efficacy of cisplatin. 16 There is an increasing interest in nanocarriers such as inorganic and polymeric nanoparticles, nanotubes, nanophosphors, liposomes, and quantum dots coated with RGD analogues as targeting and imaging agents. 14, 15, [17] [18] [19] [20] [21] [22] [23] [24] Because polymeric nanoparticles are promising carriers for anticancer agents with significantly improved drug selectivity and controlled release, 25 we were motivated to investigate RGD-modified polymeric nanoparticles as cisplatin delivery vehicles. Nanocarriers with RGD ligands for the delivery of drugs have many advantages. 26 More drug molecules can be delivered per internalizing receptor, and the carriers are more likely to be internalized via receptormediated endocytosis than single RGD constructs owing to higher local ligand concentration and receptor cross-linking. 27 The physicochemical properties of nanocarriers including their size, charge, porosity, surface hydrophilicity, and rigidity impact their pharmacokinetic and biodistribution properties in vivo. Optimization of these properties can result in the accumulation of nanocarriers in tumor tissue via the enhanced permeability and retention (EPR) phenomenon. 28 EPR is mediated by the leaky neovasculature, which is characteristic of tumors, resulting in nanocarrier extravasation into tumor interstitium and in the presence of poorly functioning lymphatic system in the tumors resulting in prolonged nanocarrier retention.
Improving the delivery of platinum-based anticancer agents by encapsulation in nanoparticles may lead to reduced side-effects and achieve greater efficacy at lower doses. 29 Despite the advantages of nanocarriers to improve the safety and efficacy of cytotoxic drugs, there have been no such technologies clinically approved for platinum chemotherapeutics. Examples in development and clinical trials include the platinum-polymer complexes (e.g. ProLindac™), apoferritin, liposomes (e.g. LipoPlatin™), dendrimers, and micelles. [30] [31] [32] In order to circumvent pathways that deactivate a platinum-based drug by premature metabolism and protect non-cancerous cells from its effects, more inert Pt(IV) complexes can be used as redox-activatable prodrugs for Pt(II). Pt(IV) nanoconstructs, such as acid-responsive polymer-Pt(IV) conjugates 33 and nanoscale coordination polymers (NCPs) with RGD targeting ligands, 34 have been reported. The former system showed increased cytotoxicity in comparison to cisplatin, whereas the latter did not.
Polymeric NPs have been used as a preferred nanoscale drug delivery vehicle especially for their excellent endocytosis, passive tumor-targeting, high encapsulation efficiency, and high stability, allowing for extended time in the circulatory system. 35 Noteworthy in this regard are controlledrelease polymeric NPs based on clinically validated biodegradable poly(D,L-lactic-co-glycolic acid) (PLGA) polyesters with the degradation products being lactic acid and glycolic acid, which are naturally occurring substances that further break down into water and carbon dioxide.
Since the encapsulation of cisplatin into the hydrophobic polymeric nanoparticles is relatively inefficient, resulting in poor drug loading, we developed a strategy that significantly improves the encapsulation efficiency and drug loading of cisplatin in biodegradable nanoparticles of PLGA-block-polyethylene glycol (PLGA-PEG). As recently reported, a hydrophobic Pt(IV) compound was encapsulated in polymeric NPs and targeted to the prostate-specific membrane antigen (PSMA) expressing cells in vitro and in vivo using 2'-fluoropyrimidine modified RNA aptamers that specifically bound the extracellular domain of PSMA. 29, 36, 37 Here, we describe the synthesis and characterization of a polymeric NP construct that encapsulates a Pt(IV) complex in the core and is targeted to α v β 3 integrin-expressing cells using the cyclic pentapeptide c(RGDfK). We further report the in vitro cytotoxicity against several breast and prostate cancer cells and the evaluation of their α v β 3 integrin expression levels, as well as the in vivo efficacy of the construct in a breast cancer xenograft model. In this work we thereby combine the approaches of active targeting of cell antigens and passive targeting by EPR, resulting in enhanced anti-tumor efficacy and reduced toxicity to normal tissues, the overall effect of which is a higher therapeutic index.
Results and discussion

Synthesis of c(RGDfK) functionalized nanoparticles with encapsulated Pt(IV) (Pt@NP-RGDfK)
A hydrophobic Pt(IV) analogue of cisplatin, In the second step, the cyclic pentapeptide c(RGDfK) was coupled to the terminal carboxyl groups of the PEG moiety in Pt@NP (Scheme 1). The resulting Pt@NP-RGDfK was used to develop NPs for active targeting of α v β 3 integrin on cancerous cells and tumor neovasculature. The cyclization of the pentapeptide improves the binding properties; c(RGDfK) is one of the most effective, artificial RGD peptides for targeting α V β 3 . 40 For comparison of in vitro effects, we also synthesized a Pt-free analogue NP-RGDfK (vide infra).
Scheme 1. Nanoprecipitation for generating Pt(IV) encapsulated nanoparticles (Pt@NP) and functionalization with c(RGDfK) (Pt@NP-RGDfK). EDC=1-ethyl-3-[3-dimethylaminopropyl]-
carbodiimide hydrochloride, NHS=N-hydroxy-succinimide. that NPs begin to aggregate and form larger particles after functionalization. This process might be caused by the change in surface charge upon functionalization with the cyclic RGD peptide. On average, however, the NP size does not vary outside the experimental error range after functionalization (cf. Table 1 ).
Figure 1. SEM images of PLGA-PEG nanoparticles with encapsulated Pt(hex) 2 , unfunctionalized (left) and c(RGDfK)-functionalized (right). Magnification x25,000, for insert x100,000, voltage 10 kV.
The peptide content of Pt@NP-RGDfK was determined by measuring arginine using a previously described fluorimetric assay (Scheme 2 and Supporting Information Figure S1 ). 41 The reagent 9,10-phenanthrene-quinone was mixed with the sample at a high pH followed by acidification to convert arginine residues to a strongly fluorescent small molecule (λ ex =312, λ em =340-570 nm). Coupling reactions that were carried out with 1.1, 2, and 4% w/w c(RGDfK) with respect to the polymer all resulted in 1% w/w yield with respect to the polymer.
Scheme 2. Reaction of arginine with 9,10-phenanthrene-quinone to yield a fluorescent product (blue).
Qualitatively, the success of the peptide coupling was also checked by measuring the ζ potential of the NPs, which is the potential difference between the dispersion medium water and the stationary layer of fluid attached to the dispersed particle. All formulations exhibited a net negative charge with
ζ potential values ranging from -41 mV to -14 mV depending on the nature of the functionalization (representative data are in Table 1 ). The data obtained for unfunctionalized NPs (Pt@NP) are similar to a literature reported value for PLGA-PEG nanoparticles of ~200 nm size having ζ=-31.4
mV. 24 Functionalization of the NPs with c(RGDfK) (Pt@NP-RGDfK) led to no significant change in size and PDI. The ζ potential, however, increased 10 to 15 mV owing to the additional positive charge from arginine in the peptide. 
Pt@NP-NHS
139 ± 2 0.05 ± 0.05 -14.3 ± 0.4
Pt@NP-RGDfK
141 ± 5 0.12 ± 0.03 -25.9 ± 0.8
To prepare for the animal studies, we evaluated the stability of the NP constructs. Daily dosing would have demanded daily synthesis if the stability were low. Storage of the new constructs for up to six days at 4 °C in water did not change the Pt concentration, as determined by AAS after filtration, the size, or the ζ potential (Table 2 ). These results indicated that the constructs remain intact during this time period and under the conditions employed. 
Integrin expression
Expression of the α v β 3 integrin was quantified by flow cytometry using the FITC conjugated mouse 
Figure 2. α v β 3 integrin expression was determined with a FITC labeled antibody and analyzed by flow cytometry. The bars represent averages from three independent experiments (cf. Supporting
Information Figure S2 for representative raw data histograms).
The α v β 3 integrin was expressed in high levels in PC3 cells (33%) and DU145 cells (46%). MCF-7 cells, however, lacked significant expression of α v β 3 . These results are in accord with literature reported values (39% and 46%, respectively, for PC3 and DU145). [42] [43] [44] [45] The α v β 3 integrin levels of cycled cells were similar to those of the parental cell lines except for PC3 cell lines, where the expression levels of the cycled cells were lower.
Immunofluorescence
Once internalized by cells, Pt@NP-RGDfK is presumed to release Pt(hex) 2 , which can be reduced to cisplatin and induce apoptosis by forming DNA adducts. The presence of Pt-1,2-d (GpG) intrastrand cross-links, the principal DNA adduct formed by cisplatin, in PC3MLN4 cells was confirmed by a monoclonal adduct-specific antibody (cf. Supporting Information, Figure S3 ). As a positive control, cisplatin was used, and a negative control did not contain any Pt compound. 2 , and Pt@NP were also tested ( Figure 3) . Cisplatin displays IC 50 values on the order of magnitude of those in the literature, ~2.8 µM for PC3, ~0.7 µM for DU145, and ~12 µM for MCF7 cells. Reported values using slightly different MTT protocols are ~1.0 µM for PC3, ~1.7 µM for DU145, 46 and ~5 µM for MCF7. 47 The Pt(IV) compound, Pt(hex) 2 , was more cytotoxic in all cell lines tested compared to the Pt(II) parental compound, cisplatin. As recently reported, the high lipophilicity of a Pt(IV) complex contributes to its increased cell killing ability. 48 The NP constructs were more active than cisplatin in all cancer cell lines. This result represents an improvement over the small molecule RGD-Pt(IV) construct that we previously reported, for which there was no increase in cytotoxicity compared to cisplatin. 16 Protection of the Pt prodrug by the NP may give rise to the improved cytotoxicity. Our construct is more effective than a similar RGD-linked nanoscale coordination polymer used for the delivery of Pt(IV) complex prodrug. 34 For example, in MCF7 cells only a 1.2-fold improvement in cytotoxicity was observed for the nanoscale coordination polymer compared to cisplatin, 34 whereas we observed an increase in cytotoxicity by factor 6 by encapsulation of the Pt(IV) complex.
The cytotoxicity of Pt@NP-RGDfK is not supposed to emanate from the polymer or the RGD targeting moiety of the NP construct. This expectation can be supported by a simple calculation. 
Figure 4. a) Effects of cisplatin and Pt@NP-RGDfK on body weight of mice bearing MCF7MFP1 xenograft. Body weight was measured at the indicated time points. b) Effects of cisplatin and
Pt@NP-RGDfK on growth of MCF7MFP1 breast cancer xenografts. A dose of 0.8 mg/kg (with respect to Pt) or saline was administered i.v. and the tumor size was measured at the indicated time points. Two mice (one in the saline, one in the cisplatin group) were disregarded for the evaluation since the tumor volume did not change within the time course.
Next, the biodistribution of the Pt@NP-RGDfK was investigated. Organ samples were dissolved in nitric acid and hydrogen peroxide and subjected to AAS analysis for Pt determination. 52 Figure 5 shows the results. Platinum accumulation in the liver was comparable for cisplatin and Pt@NP-RGDfK, whereas lower Pt uptake in the heart, kidney, spleen and lung was observed for the NP system. The low impact on the latter organs has also been observed in a similar NP system comprising RNA aptamers instead of peptides as targeting moieties. 29 
Figure 5. Distribution of Pt in mouse organs at 0.8 mg/kg dose cisplatin and Pt@NP-RGDfK (average and standard deviation for 5 mice/group).
The Pt content in the kidney was lower by factor of 10 for the NP construct than for cisplatin. This result is significant because a dose-limiting side-effect of cisplatin is nephrotoxicity. Because of possible filtration through liver and kidney excretion, particle size is a key factor. Intuitively, smaller nanoparticles enter cells more easily than larger nanoparticles, whereas the larger particles favourably target the tumor due to enhanced permeability and impaired lymphatic drainage (EPR effect). Polymeric NPs in the size range of 100-200 nm have the highest potential for long-time circulation because they are big enough to avoid uptake in the liver and rapid renal clearance, 25 but small enough to avoid filtering in the spleen. 53 NPs of a size of up to 100-200 nm can be taken up by cells via receptor-mediated endocytosis, 54 whereas the best EPR effect for a rigid particle is achieved for sizes < 400 nm. 25 Particles with an average size of ~100 nm thus fulfill both restrictions and at the same time ensure good drug load and controlled release. Our nanoparticle system, exhibiting sizes of 75-140 nm, might therefore provide a more favorable biodistribution compared to that of cisplatin. Other biophysical properties like charge, surface hydrophilicity, and density of ligands on the surface of a NP can, however, also impact the biodistribution. These parameters are difficult to evaluate in the present study. 
Experimental Section
Methods and materials
Glycine buffer (Sörensen's glycine buffer) was prepared from 0. 
Synthesis of nanoparticles NP, Pt@NP, NP-RGDfK, Pt@NP-RGDfK
Nanoparticles were prepared using the nanoprecipitation method as reported previously. 36, 37 Briefly, the copolymer PLGA-PEG and Pt(hex) 2 were dissolved in acetonitrile at a final concentration of 5 mg/mL polymer and 30-50% w/w complex with respect to the polymer. The resulting solution was added to a tenfold higher volume of MilliQ-water and stirred for up to four hours. Alternatively, an Ultra-Turrax dispersing tool (T25 basic) at velocities of 6.5, 9.5, 13.5, 17.5, 21.5, 24 k·min -1 was used. The NP suspension was filtered through filter paper and washed three times in Amicon centrifugal filter units MWCO 100 kDa at 3000 rpm and 4 °C. Alternatively, the ultrafiltration was carried out in a stirred ultrafiltration cell 8400 (Millipore, Billerica, MA) using a Similarly, a Pt-free construct (NP), and a Pt-free but RGD-conjugated construct (NP-RGDfK), were synthesized, omitting the Pt(hex) 2 solution during the nanoprecipitation step.
Arginine determination
The peptide content of the nanoparticles was determined by measuring the arginine content as described previously. 41 Briefly, 50 µL samples were mixed with 150 µL 9,10-phenanthrenequinone Figure S1 ).
Scanning electron microscopy (SEM)
Samples for SEM were prepared by dropping a NP suspension onto a polished silicon wafer.
Scanning electron microscopy images were obtained with a JEOL JSM6700F electron microscope operated at 10 kV.
Dynamic light scattering (DLS)
DLS for size determination and ζ potential measurements was performed on a Malvern Zetasizer Nano ZS90 instrument (Malvern Instruments, Malvern, UK).
Cell culture
Cells were cultured in DMEM (Dulbecco's Modified Eagle Medium) (MCF7 and MCF7MFP1) or RPMI-1640 (DU145, DU145LN2, PC3, PC3MLN4) containing 4.5 g/L glucose and L-glutamine, no sodium pyruvate, 10% FBS, 100 units/mL penicillin, and 100 µg/mL streptomycin (all from Cellgro, Manassas, VA, USA) at 37 °C, in a humidified atmosphere at 5% CO 2 .
Flow cytometry
Cells were harvested from T-25 flasks by trypsin treatment, counted, and washed with ice-cold PBS/5%FBS/0. 
Immunofluorescence
The detection of Pt-1,2-d(GpG) cross-links on the DNA of PC3MLN4 cells was achieved by following a procedure similar to one previously reported using an adduct specific antibody. 
Cytotoxicity tests 58
The cells were plated in flat-bottomed 96-well plates starting with column 2 and ending with column 11 (1,000 cells/well for prostate cancer cells, 2,000 cells/well for slower growing breast cancer cells). The plates were incubated at 37 °C for 2 -3 d such that cells were in the exponential phase of growth for drug addition. A serial four-fold dilution of the compound to be tested in growth medium was prepared to give eight concentrations of 2 mL each (1.5 mL medium + 0.5 mL drug dilution, 0.006-100 µM for Pt or peptide, 0.12-2,000 µg/mL for polymeric material). The medium was removed from all wells, and the drug was added in the several dilutions in fresh growth medium. The plates were incubated for 72 h. At the end of the drug-exposure period the medium was removed and the plates were treated with 200 µL of MTT solution (stock 1:5 in medium). The plates were incubated for 4 h in a humidified atmosphere at 37 °C. The medium was removed from the wells and the purple MTT-formazan crystals were dissolved by addition of 200 µL DMSO/glycine buffer pH 10.5 (8:1). Since the absorption spectrum of MTT-formazan is pHdependent, and the pH varies with the cell density in the well, the pH in all wells was adjusted to 10.5 where the spectrum shows only a single peak at 570 nm. 58 The absorbance was measured at this maximum on a SynergyHT platereader (BioTek, Winooski, VT), and the mean absorbance reading from the wells without drug was used as the control (100% viability). IC 50 values were determined by interpolation of the resulting curves.
Animal Studies
Female nude mice (8 weeks old) were obtained from Charles River Laboratories (Wilmington, MA, USA) and were allowed to acclimate for at least 5 days. They were housed under aseptic conditions and given autoclaved rodent diet and sterile water ad libitum. given day and C is the mean tumor size for the control group. Mice were sacrificed by CO 2 inhalation when their tumors reached the 300 mm 3 endpoint value or after 7 weeks.
All animal procedures were approved by the Children's Hospital Boston Animal Care and Use
Committee (IACUC) and the Committee on Animal Care at MIT.
Analysis of Pt content in mouse organs
Organ samples of all 15 mice were prepared for analysis of their Pt content by AA similar to a procedure published previously. 52 A 200 mg tissue sample was incubated in 500 µL concentrated nitric acid overnight at room temperature. The sample was boiled for 3 min, cooled to room temperature, and 500 µL 30% hydrogen peroxide was added. After boiling for 5 min the volume was adjusted to 1 mL with MilliQ water. The furnace parameters for the AA measurement were as reported before, 52 
